The salient findings in this study are that (1) short-term intermittent administration of the quinoxaline GLP-1 receptor agonist (DMB) after infarction attenuates adverse remodeling and improves cardiac function; (2) DMB enhances autophagy, mitophagy, and mitochondrial biogenesis; (3) the salutary effects of DMB on remodeling were lost in Parkin knockout mice, suggesting that the beneficial effects are dependent on Parkin-mediated mitophagy and (4) Parkin loss also negatively impacts DMB-mediated mitochondrial biogenesis. Here, GLP1R is linked to infarction.